Cured but breathless: the growing burden of DIILD in cancer survivors

Abstract

Drug-induced interstitial lung disease (DIILD) is emerging as a hidden toll of modern oncology. Diagnosis of DIILD is confounded by non-specific symptoms and the absence of validated biomarkers, leaving clinicians to navigate heterogeneous, drug-specific guidelines. Herein, we discuss this predicament and advocate a shift from reactive management towards proactive survivorship.